Paris, France

Céline Anquetil

This inventor holds 1 USPTO granted patent. Top assignees: Assistance Publique-Hopitaux De Paris, Institut National De La Santé Et De La Recherche Médicale (Inserm), Sorbonne Université. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Céline Anquetil. Retrieved from https://idiyas.com/inventor/céline-anquetil

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Céline Anquetil: Research and Patent Activity in Paris

Introduction

Céline Anquetil is an inventor based in Paris, France. Her patent activity includes work on managing immune-related toxicities associated with cancer immunotherapy.

Latest Patents

Anquetil is named on one patent, “Method for Treating Immune Toxicities Induced by Immune Checkpoint Inhibitors.” The invention concerns using a JAK inhibitor to treat or prevent adverse events in patients receiving immune checkpoint inhibitors, or to treat cancer in combination with an immune checkpoint inhibitor. The patent record lists 1 patent.

Career Highlights

The information provided associates Anquetil with Assistance Publique–Hôpitaux de Paris and Sorbonne Université. These institutions are connected with her professional and research context.

Collaborations

Her listed coworkers include Yves Allenbach and Joe-Elie Salem. Their names appear alongside Anquetil in the supplied information about her professional collaborations.

Conclusion

Céline Anquetil’s patent work focuses on approaches to addressing immune toxicities and supporting cancer treatment involving immune checkpoint inhibitors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…